63 results match your criteria rvsv-zebov


Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.

Front Immunol 2021 16;12:706757. Epub 2021 Jul 16.

The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, United States.

Three clinically relevant ebolaviruses - Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease and occasional deadly outbreaks in Africa. The largest Ebola virus disease (EVD) epidemic to date in 2013-2016 in West Africa highlighted the urgent need for countermeasures, leading to the development and FDA approval of the Ebola virus vaccine rVSV-ZEBOV (Ervebo) in 2020 and two monoclonal antibody (mAb)-based therapeutics (Inmazeb [atoltivimab, maftivimab, and odesivimab-ebgn] and Ebanga (ansuvimab-zykl) in 2020. The humoral response plays an indispensable role in ebolavirus immunity, based on studies of mAbs isolated from the antibody genes in peripheral blood circulating ebolavirus-specific human memory B cells. Read More

View Article and Full-Text PDF

Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.

J Travel Med 2021 Jun 15. Epub 2021 Jun 15.

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland.

Background And Rationale: Geneva University Hospitals were granted a temporary authorization to administer the recombinant live vesicular stomatitis virus rVSV-ZEBOV (Ervebo®) vaccine to expatriate humanitarian frontline workers (FLWs) prior to mission deployment.

Objectives: Our aims were to assess the feasibility of FLW vaccination before deployment and to report adverse events (AEs).

Methods: FLWs received a single injection of rVSV-ZEBOV (>7. Read More

View Article and Full-Text PDF

Ebola virus disease: current vaccine solutions.

Curr Opin Immunol 2021 Aug 17;71:27-33. Epub 2021 Apr 17.

Infectious Diseases and Environmental Health Research Group (IDEHRG), Department of Microbiology, University of Ilorin, Ilorin, Kwara State, Nigeria.

Ebola Virus Disease (EVD) is an emerging zoonotic disease with intermittent outbreaks in Central and West African countries. The unpredictable high case fatality rate has made it a disease of public health concern. Different vaccine platforms have shown prophylactic protection in human and non-human primates, with the progress towards a licensed vaccine greatly accelerated in response to the devastating outbreak of EVD in West Africa from 2013-2016. Read More

View Article and Full-Text PDF

Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.

Biotechnol Bioeng 2021 07 5;118(7):2649-2659. Epub 2021 May 5.

Department of Bioengineering, McGill University, Montreal, Quebec, Canada.

The Vero cell line is the most used continuous cell line in viral vaccine manufacturing. This adherent cell culture platform requires the use of surfaces to support cell growth, typically roller bottles, or microcarriers. We have recently compared the production of rVSV-ZEBOV on Vero cells between microcarrier and fixed-bed bioreactors. Read More

View Article and Full-Text PDF

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.

N Engl J Med 2021 04;384(13):1240-1247

From the Institut National de Recherche Biomédicale (P.M.-K., A.N.-N., E.K.-L., A.A., D.M., N.B., D.K., B.N., M.A., O.T., S.M, S.A.-M., J.-J.M.T.), the University of Kinshasa (P.M.-K., A.N.-N., F.M., F.E., M.M., J.B.B., S.A.-M., J.-J.M.T.), and Ministère de la Santé (F.B., V.E., E.S.-P., Y.T.T.N.) - all in Kinshasa, Democratic Republic of Congo; the University of Nebraska Medical Center, Omaha (C.P., B.W., M.R.W.); International Medical Corps (M.M.-R.) and the University of California, Los Angeles (A.W.R., M.A.S.), Los Angeles, and the Scripps Research Institute, La Jolla (M.G.P., K.G., E.S., A.T., K.G.A.) - all in California; the Fred Hutchinson Cancer Research Center, Seattle (A.B., J.H., T.B.); the Institut Pasteur de Dakar, Dakar, Senegal (M.F., M.M.D., O.F., A.S.); the Vaccine Research Center, National Institutes of Health, Bethesda (J.M., A.P., N.J.S.), and the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research (I.C.), and the Integrated Research Facility at Fort Detrick, National Institutes of Health (L.H.), Frederick - all in Maryland; the World Health Organization, Geneva (B.D., M.K., M.R.D.B., I.S.F., A.Y.); and the University of Edinburgh, Edinburgh, United Kingdom (A.R.).

During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. Read More

View Article and Full-Text PDF

Prominent Neutralizing Antibody Response Targeting the Glycoprotein Subunit Interface Elicited by Immunization.

J Virol 2021 Feb 3. Epub 2021 Feb 3.

Institute for Bioscience and Biotechnology Research, Rockville, MD

The severe death toll caused by the recent outbreak of Ebola virus disease reinforces the importance of developing ebolavirus prevention and treatment strategies. Here, we have explored the immunogenicity of a novel immunization regimen priming with vesicular stomatitis virus particles bearing Sudan Ebola virus (SUDV) glycoprotein (GP) that consists of GP1 & GP2 subunits and boosting with soluble SUDV GP in macaques, which developed robust neutralizing antibody (nAb) responses following immunizations. Moreover, EB46, a protective nAb isolated from one of the immune macaques, is found to target the GP1/GP2 interface, with GP-binding mode and neutralization mechanism similar to a number of ebolavirus nAbs from human and mouse, indicating that the ebolavirus GP1/GP2 interface is a common immunological target in different species. Read More

View Article and Full-Text PDF
February 2021

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.

bioRxiv 2021 Jan 19. Epub 2021 Jan 19.

The ongoing pandemic of Coronavirus disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent discussions concerning vaccination strategies have focused on identifying vaccine platforms, number of doses, route of administration, and time to reach peak immunity against SARS-CoV-2. Read More

View Article and Full-Text PDF
January 2021

Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.

Vaccine 2020 11 1;38(50):7949-7955. Epub 2020 Nov 1.

Department of Bioengineering, McGill University, Montreal, QC, Canada. Electronic address:

Acquired Immune Deficiency Syndrome (AIDS) in humans is a result of the destruction of the immune system caused by Human Immunodeficiency Virus (HIV) infection. This serious epidemic is still progressing world-wide. Despite advances in treatment, a safe and effective preventive HIV vaccine is desired to combat this disease, and to save millions of lives. Read More

View Article and Full-Text PDF
November 2020

Modelling the daily risk of Ebola in the presence and absence of a potential vaccine.

Infect Dis Model 2020 15;5:905-917. Epub 2020 Oct 15.

Department of Mathematics and Faculty of Medicine, The University of Ottawa, 150 Louis-Pasteur Pvt, Ottawa, ON, K1N6N5, Canada.

Ebola virus - one of the deadliest viral diseases, with a mortality rate around 90% - damages the immune system and organs, with symptoms including episodic fever, chills, malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine (rVSV-ZEBOV) has demonstrated clinical efficacy against Ebola in ring-vaccination clinical trials. In order to evaluate the potential effect of this candidate vaccine, we developed risk equations for the daily risk of Ebola infection both currently and after vaccination. Read More

View Article and Full-Text PDF
October 2020

Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting.

Vaccine 2020 10 18;38(45):7166-7174. Epub 2020 Sep 18.

Vaccine Analytical Research Development and Vaccine Process Development and Commercialization, Merck & Co., Inc., Kenilworth, NJ, USA.

Ebolavirus (EBOV) entry to host cells requires membrane-associated glycoprotein (GP). A recombinant vesicular stomatitis virus vector carrying Zaire Ebola virus glycoprotein (rVSV-ZEBOV) was developed as a vaccine against ebolaviruses. The VSV glycoprotein gene was deleted (rVSVΔG) and ZEBOV glycoprotein (GP) was inserted into the deleted VSV glycoprotein open reading frame (ORF) resulting in a live, replication-competent vector (rVSVΔG-ZEBOV-GP). Read More

View Article and Full-Text PDF
October 2020

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins.

Viruses 2020 08 20;12(9). Epub 2020 Aug 20.

Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013-2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. Read More

View Article and Full-Text PDF

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment.

Nat Commun 2020 07 27;11(1):3736. Epub 2020 Jul 27.

Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0610, USA.

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Read More

View Article and Full-Text PDF

Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution.

Biotechnol J 2020 Sep 8;15(9):e2000069. Epub 2020 Jun 8.

Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems, Potsdam, 14476, Germany.

The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti-EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Read More

View Article and Full-Text PDF
September 2020

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.

NPJ Vaccines 2020 14;5(1):32. Epub 2020 Apr 14.

1Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56 NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR) cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR CD56 or cytokine-responsive CD56 NK cells. Read More

View Article and Full-Text PDF

Titration methods for rVSV-based vaccine manufacturing.

MethodsX 2020 20;7:100806. Epub 2020 Feb 20.

Department of Bioengineering, McGill University, 3480 University, Montréal, Québec H3A 0E9, Canada.

The recombinant Vesicular Stomatitis Virus (rVSV) is an emerging platform for viral vector-based vaccines. Promising results have been reported in clinical trials for the rVSV-ZEBOV vaccine for Ebola virus disease prevention. In this study, we describe the titration tools elaborated to assess the titre of rVSV-ZEBOV productions. Read More

View Article and Full-Text PDF
February 2020

Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.

Vaccine 2020 03 21;38(14):3003-3007. Epub 2020 Feb 21.

Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada; School of Public Health, University of Alberta, Edmonton, AB, Canada; Distinguished Researcher, Stollery Science Lab, University of Alberta, Edmonton, AB, Canada; Women and Children's Research Institute, University of Alberta, Edmonton, AB, Canada. Electronic address:

The second largest Ebolavirus disease (EVD) outbreak ever recorded is currently ongoing in Eastern Democratic Republic of the Congo (DRC). This is the first outbreak for which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) candidate vaccine has been widely administered, using a ring vaccination strategy. We examined whether prior vaccination with rVSV-ZEBOV impacts viral load, organ impairment, and survival among patients with EVD admitted to Ebola Treatment Units (ETUs) in the DRC. Read More

View Article and Full-Text PDF

Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.

J Biotechnol 2020 Feb 30;310:32-39. Epub 2020 Jan 30.

Department of Bioengineering, McGill University, Montreal, QC, Canada. Electronic address:

Ebola virus disease outbreaks have repeatedly occurred on the African continent over the last decades, with more serious outbreaks in recent years. Being highly transmissible and associated to high fatality rates, it constitutes a serious threat to public health. Vaccination, however, may allow for efficient control of its propagation. Read More

View Article and Full-Text PDF
February 2020

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas.

Authors:
David A Schwartz

Vaccines (Basel) 2020 Jan 22;8(1). Epub 2020 Jan 22.

Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

The Ebola virus disease (EVD) outbreak that began in Kivu province of the Democratic Republic of the Congo (DRC) in July 2018 is the second largest in history. It is also the largest and most deadly of the ten Ebola outbreaks to occur in DRC, the country where Ebola was first identified during the 1976 Yambuku outbreak. The Kivu region is one of the most challenging locations in which to organize humanitarian assistance. Read More

View Article and Full-Text PDF
January 2020

From discovery to delivery: public sector development of the VSV-ZEBOV Ebola vaccine.

J Law Biosci 2020 Jan-Dec;7(1):lsz019. Epub 2020 Jan 16.

Faculty of Law and Faculty of Medicine, McGill University.

The discovery and development of the Ebola VSV-ZEBOV vaccine challenge the common assumption that the research and development for innovative therapeutic products and vaccines is best carried out by the private sector. Using internal government documents obtained through an access to information request, we analyze the development of VSV-ZEBOV by researchers at Canada's National Microbiology Laboratory beyond its patenting and licensing to a biotech company in the United States in 2010. According to government documentation, the company failed to make any progress toward a phase 1 clinical trial until after the WHO Public Health Emergency of International Concern freed substantial donor and public funds for the vaccine's further development. Read More

View Article and Full-Text PDF
January 2020

Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges.

AIMS Public Health 2019 20;6(4):502-513. Epub 2019 Nov 20.

Department of Internal Medicine, Medical School Hospital, University of Kinshasa, Kinshasa, Congo.

The current Ebolavirus disease (EVD) outbreak in the provinces of North Kivu and Ituri is the tenth outbreak affecting the Democratic Republic of Congo (DRC); the first outbreak occurring in a war context, and the second most deadly Ebolavirus outbreak on record following the 2014 outbreak in West Africa. The DRC government's response consisted of applying a package of interventions including detection and rapid isolation of cases, contact tracing, population mapping, and identification of high-risk areas to inform a coordinated effort. The coordinated effort was to screen, ring vaccinate, and conduct laboratory diagnoses using GeneXpert (Cepheid) polymerase chain reaction. Read More

View Article and Full-Text PDF
November 2019

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.

Clin Infect Dis 2020 12;71(11):2872-2879

Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.

Background: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk.

Methods: Approval for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. Read More

View Article and Full-Text PDF
December 2020

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.

Nat Med 2019 10 7;25(10):1589-1600. Epub 2019 Oct 7.

Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. Read More

View Article and Full-Text PDF
October 2019

Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.

Vaccine 2019 10 20;37(44):6624-6632. Epub 2019 Sep 20.

Department of Bioengineering, McGill University, Montreal, QC, Canada. Electronic address:

Ebola virus disease is an urgent international priority. Promising results for several vaccine candidates have been reported in non-human primate studies and clinical trials with the most promising being the rVSV-ZEBOV vaccine. In this study, we sought to produce rVSV-ZEBOV in HEK 293SF cells in suspension and serum-free media. Read More

View Article and Full-Text PDF
October 2019

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Vaccine X 2019 Apr 29;1:100009. Epub 2019 Jan 29.

Independent Expert, United Kingdom.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant vesicular stomatitis virus (rVSV) as a chimeric virus vaccine for HIV-1 (Clarke et al., 2016). Read More

View Article and Full-Text PDF

Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

Vaccine 2019 11 16;37(47):6942-6950. Epub 2019 Jul 16.

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, United States. Electronic address:

Ebola virus (EBOV) is among the deadliest pathogens known to man causing infrequent outbreaks of hemorrhagic disease. In humans, the case fatality rates in the outbreaks can reach 90%. During the West African epidemic almost 30,000 people were infected and of these over 11,000 fatalities were reported. Read More

View Article and Full-Text PDF
November 2019

Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine.

Vaccine 2019 04 13;37(16):2174-2178. Epub 2019 Mar 13.

Department of Pediatrics, University of Alberta, Edmonton, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada; School of Public Health, University of Alberta, Edmonton, Canada. Electronic address:

Background: The current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine.

Methods: Cross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC. Read More

View Article and Full-Text PDF

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Expert Rev Vaccines 2018 12 15;17(12):1105-1110. Epub 2018 Nov 15.

b Centre for Vaccinology , University Hospitals and University of Geneva , Geneva , Switzerland.

Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Areas Covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. Read More

View Article and Full-Text PDF
December 2018

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.

Vaccine 2019 11 25;37(48):7171-7177. Epub 2018 Sep 25.

Epicentre, 8 rue Saint Sabin, 75011 Paris, France. Electronic address:

Background: As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP. Here we summarize the information on the safety follow-up.

Methods: An open-label, non-randomized, immunogenicity evaluation of one dose of rVSVΔG/ZEBOV-GP was conducted in Conakry, Guinea between March 2015 and July 2016. Read More

View Article and Full-Text PDF
November 2019

A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.

J Infect Dis 2018 11;218(12):1883-1889

Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Recent West African Ebola virus (EBOV) epidemics have led to testing different anti-EBOV vaccines, including a replication-defective adenovirus (RD-Ad) vector (ChAd3-EBOV) and an infectious, replication-competent recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (rVSV-EBOV; also known as rVSV-ZEBOV). While RD-Ads elicit protection, when scaled up to human trials, the level of protection may be much lower than that of vaccines containing viruses that can replicate. Although a replication-competent Ad (RC-Ad) vaccine might generate a level of protection approximating that of rVSV, this infectious vector would also risk causing adenovirus disease. Read More

View Article and Full-Text PDF
November 2018